Companion Society Meetings

Pancreatobiliary Pathology Society

Pancreatobiliary Neoplasia: I. From molecules and morphology: An update
II. Interactive discussion on staging impacting grossing

Saturday, March 17, 2018, 7:00 - 10:00 PM

Session Credits:

3 CME and 3 SAMs

Moderator:

Olca Basturk, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Course Description:

The Pancreatobiliary Pathology Society executive committee members determined the title, contents and speakers of this companion meeting. The target audience includes academic pathologists, practicing pathologists, and pathology residents and fellows who have interests in the pathology of pancreatobiliary neoplasms.

In the past decade, diagnosis and classification of pancreatic neoplasia has changed significantly. The pancreas luncheons held in the past few years highlighted the importance of these changes and the necessity for pathologists to become familiar with these developments. In this session, two recent major developments will be addressed. In the first part of the meeting, molecular discoveries that took place in the past few years, which will potentially impact not only the way we view these tumors but also the way we diagnose them in daily practice, will be addressed by three speakers. Dr. Hruban will focus on recent molecular-genetic discoveries regarding pancreatic ductal adenocarcinoma. Dr. Günter Klöppel will address the molecular tumorigenesis of pancreatic neuroendocrine neoplasia and its implications on their diagnosis and prognostication. Dr. Olca Basturk will cover the molecular basis of intraductal neoplasia and how these relate to the classification and terminology of these tumors. In the second part, which will be conducted as an interactive session, AJCC/UICC 8th edition, which will go into effect in January 2018, will be covered. The role of grossing in accomplishing accurate staging of pancreatobiliary tumors will be emphasized.

Learning Objectives:

Upon completion of this educational activity, the learner will be able to:

  • Update their knowledge on the novel genomic data in pancreatic ductal adenocarcinomas and its implications for diagnosis and therapy
  • Have an overview of the main molecular events in neuroendocrine neoplasia and their impact on classification, risk stratification and therapy
  • Describe key histopathologic and genetic features that help diagnosing and classifying pancreatobiliary intraductal neoplasia
  • Describe dissection of pancreas resections to ensure accurate tumor identification, sampling, and nodal yield

 

7:00 PM Pancreatic Cancer Genetics: The Long and Winding Road
Ralph Hruban, MD, Johns Hopkins University, Baltimore, MD
8:00 PM Genomic Profiling of Intraductal Pancreatobiliary Neoplasms
Olca Basturk, MD, Memorial Sloan Kettering Cancer Center, New York, NY
9:00 PM Molecular Signatures in PanNENs
Günter Klöppel, MD, University of Kiel, Kiel, Germany

 

Continuing Medical Education and Maintenance of Certification

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The United States and Canadian Academy of Pathology and Pancreatobiliary Pathology Society. The United States and Canadian Academy of Pathology is accredited by the ACCME to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this live activity for a maximum of
3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Maintenance of Certification (MOC). Physicians must take and pass the post-test in order to claim SAMs credit.

Physicians can earn a maximum of 3 SAM credit hours.

 

Return to 2018 Annual Meeting Companion Society Meetings Page

Meetings

view more